Goldman Sachs Group Inc vs Stryker Corporation — how do they compare? Goldman Sachs Group Inc trades at $889.79 (market cap $256.98B), while Stryker Corporation trades at $279.07 (market cap $106.24B). The key difference: Goldman Sachs Group Inc is far larger — about 2.4× Stryker Corporation's market cap, and Goldman Sachs Group Inc pays the higher dividend (2.27%). Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 101 Days and Stryker Corporation for 20 Days on average.
| GS | SYK | |
|---|---|---|
Market Cap | $256.98B | $106.24B |
Volume | 1,748,426 | 2,982,001 |
Sector | Financials | Health |
52-Week High | $1.15K | $388.35 |
52-Week Low | $744.60 | $269.75 |
Typical Hold Time | 101 Days | 20 Days |
Enterprise Value | $814.98B | $117.70B |
Dividend Yield | 2.27% | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $887.21, down 1.11% on the day, with a bearish technical signal despite strong fundamental performance. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $20.98 significantly exceeding expectations of $14.47. Revenue growth accelerated to $58.28 billion in 2025, while net income margin improved to 29.46%. Analyst consensus remains positive with a $1,130 price target, though technical indicators show selling pressure.
GS presents a compelling value opportunity with a P/E of 13.63 below industry averages, supported by robust earnings growth and a 31.68% net income margin. However, negative operating cash flow of -$45.15 billion in 2025 and bearish technical momentum create near-term headwinds. The stock's 18.33% ROE and dividend yield of approximately 0.56% provide shareholder returns, but investors should monitor cash flow trends and FICC business performance highlighted in recent management commentary.
Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.
Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →